Most cited papers from AC Immune (Switzerland)

AC Immune (Switzerland)

What are the most cited papers from AC Immune (Switzerland)?

The most cited paper from AC Immune (Switzerland) is "Mapping microglia states in the human brain through the integration of high-dimensional techniques" (Roman Sankowski, Chotima Böttcher, Takahiro Masuda et al., 2019), with 477 citations. Next come "An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A" (317) and "Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy" (258).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 24 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Mapping microglia states in the human brain through the integration of high-dimensional techniques Roman Sankowski, Chotima Böttcher, Takahiro Masuda et al. · Nature Neuroscience Open access	18 Nov 2019	477
2	An Effector-Reduced Anti- -Amyloid (A ) Antibody with Unique A Binding Properties Promotes Neuroprotection and Glial Engulfment of A Oskar Adolfsson et al. · Journal of Neuroscience Open access	11 Jul 2012	317
3	Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy Clara Theunis, Natàlia Crespo‐Biel, Valérie Gafner et al. · PLoS ONE Open access	19 Aug 2013	258
4	Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration Danielle E. Mor, Elpida Tsika, Joseph R. Mazzulli et al. · Nature Neuroscience Open access	18 Sep 2017	229
5	Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies Heiko Kroth, Felix Oden, Jérôme Molette et al. · European Journal of Nuclear Medicine and Molecular Imaging Open access	Jul 2019	228
6	Tau PET imaging with 18 F-PI-2620 in Patients with Alzheimer Disease and Healthy Controls: A First-in-Humans Study André Mueller, Santiago Bullich, Olivier Barret et al. · Journal of Nuclear Medicine Open access	11 Nov 2019	206
7	Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice Andreas Muhs, David T. Hickman, Maria Pihlgren et al. · Proceedings of the National Academy of Sciences Open access	22 May 2007	178
8	Aβ42 Neurotoxicity Is Mediated by Ongoing Nucleated Polymerization Process Rather than by Discrete Aβ42 Species Asad Jan, Oskar Adolfsson, Igor Allaman et al. · Journal of Biological Chemistry Open access	15 Dec 2010	176
9	The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases Ruben A Smith et al. · Nature Communications Open access	27 Oct 2023	149
10	Aβ and tau prion-like activities decline with longevity in the Alzheimer’s disease human brain Atsushi Aoyagi, Carlo Condello, Jan Stöhr et al. · Science Translational Medicine Open access	May 2019	149
11	Protein-inspired antibiotics active against vancomycin- and daptomycin-resistant bacteria Mark A. T. Blaskovich et al. · Nature Communications Open access	27 Dec 2017	148
12	Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement Seung-Hye Lee et al. · Cell Reports Open access	28 Jul 2016	135
13	Chemistry and Pharmacology of GABAB Receptor Ligands Wolfgang Froestl · Advances in pharmacology Book chapter	2010	123
14	Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin Mark H. Ultsch, Bing Li, Till Maurer et al. · Scientific Reports Open access	20 Dec 2016	122
15	Suppression of protein aggregation by chaperone modification of high molecular weight complexes John Labbadia, Sergey S. Novoselov, John S. Bett et al. · Brain Open access	6 Mar 2012	119
16	Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease Gai Ayalon et al. · Science Translational Medicine Open access	12 May 2021	112
17	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease Pieter Jelle Visser et al. · Molecular Neurodegeneration Open access	28 Mar 2022	98
18	Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors Wolfgang Froestl, Andreas Muhs, Andrea Pfeifer · Journal of Alzheimer s Disease	14 Nov 2012	91
19	An Historical Perspective on Gabaergic Drugs Wolfgang Froestl · Future Medicinal Chemistry	Feb 2011	87
20	Structural Selection in G‐Quartet‐Based Hydrogels and Controlled Release of Bioactive Molecules Nampally Sreenivasachary, Jean‐Marie Lehn · Chemistry - An Asian Journal	19 Dec 2007	84
21	Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases David T. Hickman, María Pilar López-Deber, Dorin Mlaki Ndao et al. · Journal of Biological Chemistry Open access	22 Feb 2011	83
22	Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting Erin T. Williams, Liliane Glauser, Elpida Tsika et al. · Human Molecular Genetics Open access	6 Jun 2018	79
23	BACE-1 is expressed in the blood–brain barrier endothelium and is upregulated in a murine model of Alzheimer’s disease Kavi Devraj, Slobodan Poznanović, Christoph K. Spahn et al. · Journal of Cerebral Blood Flow & Metabolism Open access	13 Oct 2015	78
24	Specific Reduction of Alcohol’s Motivational Properties by the Positive Allosteric Modulator of the GABAB Receptor, GS39783—Comparison With the Effect of the GABAB Receptor Direct Agonist, Baclofen Paola Maccioni, Noemi Fantini, Wolfgang Froestl et al. · Alcoholism Clinical and Experimental Research Open access	8 Jul 2008	71
25	Antidepressant‐like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents Gabriel Nowak, Anna Partyka, Agnieszka Pałucha-Poniewiera et al. · British Journal of Pharmacology Open access	29 Aug 2006	69
26	Interfacial mechanism of lipolysis as self-regulated process Pablo Victor Mendes dos Reis, Heribert J. Watzke, Martin E. Leser et al. · Biophysical Chemistry	Feb 2010	69
27	Reduction of Alcohol’s Reinforcing and Motivational Properties by the Positive Allosteric Modulator of the GABABReceptor, BHF177, in Alcohol‐Preferring Rats Paola Maccioni, Mauro A.M. Carai, Klemens Kaupmann et al. · Alcoholism Clinical and Experimental Research	Jul 2009	65
28	Discovery and Structure Activity Relationship of Small Molecule Inhibitors of Toxic β-Amyloid-42 Fibril Formation Heiko Kroth, Annalisa Ansaloni, Yvan Varisco et al. · Journal of Biological Chemistry Open access	14 Aug 2012	62
29	Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome Michael S. Rafii et al. · JAMA Neurology Open access	9 May 2022	59
30	DyNAs: Constitutional Dynamic Nucleic Acid Analogues Nampally Sreenivasachary, David T. Hickman, Dominique Sarazin et al. · Chemistry - A European Journal	12 Sep 2006	59
31	Motifs in the tau protein that control binding to microtubules and aggregation determine pathological effects Aurélien Lathuilière, Pamela Valdés, Stéphanie Papin et al. · Scientific Reports Open access	13 Oct 2017	56
32	Calpain-mediated tau fragmentation is altered in Alzheimer’s disease progression Hsu-Hsin Chen, Peter Xiaoping Liu, Paul Auger et al. · Scientific Reports Open access	7 Nov 2018	54
33	Reducing effect of the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in alcohol-preferring rats Paola Maccioni, Daniela Pes, Alessandro Orrù et al. · Psychopharmacology	29 Mar 2007	53
34	Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in rats Styliani Vlachou, Sébastien Guery, Wolfgang Froestl et al. · Psychopharmacology Open access	21 Dec 2010	52
35	An Anti-β-Amyloid Vaccine for Treating Cognitive Deficits in a Mouse Model of Down Syndrome Pavel V. Belichenko et al. · PLoS ONE Open access	29 Mar 2016	49
36	Dynamic Nuclear Polarization NMR Spectroscopy: Revealing Multiple Conformations in Lipid‐Anchored Peptide Vaccines Eline J. Koers, María Pilar López-Deber, Markus H. Weingarth et al. · Angewandte Chemie International Edition Open access	23 Aug 2013	48
37	Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin Konstantina C. Fylaktakidou, Jean‐Maríe Lehn, Ruth Greferath et al. · Bioorganic & Medicinal Chemistry Letters	21 Feb 2005	47
38	TLR4- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell–independent isotype switch in mice Maria Pihlgren, Alberto B. Silva, Rime Madani et al. · Blood Open access	9 Nov 2012	44
39	Attenuation of cocaine-seeking by GABAB receptor agonists baclofen and CGP44532 but not the GABA reuptake inhibitor tiagabine in baboons Elise M. Weerts, Wolfgang Froestl, Barbara J. Kaminski et al. · Drug and Alcohol Dependence Open access	17 Jan 2007	41
40	Evaluation of Dosimetry, Quantitative Methods, and Test–Retest Variability of 18F-PI-2620 PET for the Assessment of Tau Deposits in the Human Brain Santiago Bullich, Olivier Barret, Cristian C. Constantinescu et al. · Journal of Nuclear Medicine Open access	11 Nov 2019	40
41	Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients Krisztián Homicskó, Georg Richtig, Felix Tuchmann et al. · Annals of Oncology Open access	Dec 2018	38
42	Total Synthesis of the Marine Diterpenoid Blumiolide C Cotinica Hamel, Evgeny V. Prusov, Jürg Gertsch et al. · Angewandte Chemie International Edition	27 Nov 2008	38
43	Quantifying the limits of CAR T-cell delivery in mice and men Liam Brown, Eamonn A. Gaffney, Ann Ager et al. · Journal of The Royal Society Interface Open access	Mar 2021	37
44	Immunotherapy targeting the C-terminal domain of TDP-43 decreases neuropathology and confers neuroprotection in mouse models of ALS/FTD Tariq Afroz et al. · Neurobiology of Disease Open access	20 Feb 2023	36
45	Chemistry of GABAB Modulators Wolfgang Froestl, Nigel G. Cooke, Stuart J. Mickel · Humana Press eBooks Book chapter	16 Nov 2007	33
46	Cognitive Enhancers (Nootropics). Part 2: Drugs Interacting with Enzymes Wolfgang Froestl, Andreas Muhs, Andrea Pfeifer · Journal of Alzheimer s Disease Open access	10 Jan 2013	32
47	The case for regulatory approval of amyloid‐lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidence Paul S. S. Aisen, Randall John Bateman, Damian C. Crowther et al. · Alzheimer s & Dementia Open access	13 Nov 2024	31
48	Synthesis of Components for the Generation of Constitutional Dynamic Analogues of Nucleic Acids David T. Hickman, Nampally Sreenivasachary, Jean‐Marie Lehn · Helvetica Chimica Acta	2008	31
49	Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study. Bridget E. Barber et al. · LSTM Online Archive (Liverpool School of Tropical Medicine)	Jun 2022	30
50	The GABABreceptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice JM Wierońska, Magdalena Kusek, Krzysztof Tokarski et al. · British Journal of Pharmacology Open access	4 Mar 2011	30

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.